CL COLGATE PALMOLIVE CO Insider Trading

Chief People Officer Sally Massey sold ~8,600 shares for $751,633, her 9th open-market sale in 36 months.

Sally Massey, Colgate's Chief People Officer, sold a significant portion of her holdings—nearly two-fifths of her stake—in a sale that continues a consistent pattern of open-market dispositions. Over the past three years, she has executed nine open-market sales with no offsetting purchases, positioning her as a net seller. Her prior sales at this ticker have produced mixed timing results: some occurred just before the stock declined, while others preceded gains, suggesting she has not consistently exited at optimal moments. The stock currently trades below its 52-week high and has declined modestly over the past quarter, creating a less favorable backdrop for interpreting this sale as opportunistic. Colgate remains a profitable company with steady revenue growth and a substantial market value, so this sale does not suggest financial distress at the company level; rather, it reflects the insider's personal portfolio decisions independent of company fundamentals.

Colgate CEO Wallace sells 45,568 shares at $93.91; stock rallied 22.5% in 30 days post-filing

Wallace Noel R., as Chairman, President & CEO, sold 45,568 shares of Colgate Palmolive at $93.91, reducing his holdings by 13.5% to 293,188 shares. The sale occurred when the stock was trading 3.2% below its 52-week high and has since appreciated $0.50 per share. Across his prior sales at Colgate, the insider's timing has been mixed—only 1 of 5 prior sales at this ticker were well-timed at the 90-day mark, with his most recent sale on 2024-11-22 followed by a 7.5% decline versus typical gains of 5.2%–14.4% on his February 2024 sales. His cross-ticker track record shows a 28.57% well-timed rate on 7 prior sales with an average 90-day return of +6.1%, suggesting modest but inconsistent selling acuity. The company's fundamentals remain stable with a P/E of 26.15 and modest 3.3% annual revenue growth, offering limited insight into executive conviction.

CHRO Sally Massey sells 8.0K shares of CL at $92.02; stock down -6.6% in 90 days post-announcement.

Sally Massey, Chief Human Resources Officer, sold 8,000 shares (35.1% of her then-holdings) on 2025-02-25 at $92.02 per share for $736,152.00. The current price of $90.20 is -17.1% from the 52-week high of $108.77, indicating a period of weakness. Massey's prior sales at CL have shown mixed timing: 3 of her 5 prior sells at this ticker exhibited negative 90-day returns (well-timed), though 2 were followed by positive returns. Her cross-ticker track record shows 60.00% well-timed sells with an average 90-day return of -0.3% across all tickers, suggesting modest predictive value. The sale itself is material—reducing her CL holdings from 22,805 to 14,805 shares—but falls within routine CHRO-level portfolio activity at a mid-cap consumer-staples holding (market cap $73.2B, P/E 21.17, recent revenue growth +3.3%).

Wallace Noel R. (CEO) sells 33,333 shares of Colgate-Palmolive at $95.00; 11.0% reduction in holdings post-transaction.

Wallace Noel R., Chairman, President & CEO, sold 33,333 shares of CL at $95.00 on 2024-11-22, reducing his holdings from 304,022 shares to 270,689 shares. The sale occurred 11.2% below the 52-week high of $108.77 and at a price 1.6% below the current price of $96.58. Notably, his prior trades at Colgate-Palmolive show poor 90-day timing patterns: all 5 prior sales at this ticker yielded positive 90-day returns (ranging from +5.2% to +14.4%), indicating the stock rose after each sale—the opposite of well-timed selling. This sale follows the same pattern, with the stock currently trading higher than his transaction price, suggesting no protective signal is present. With a P/E of 27.52 and strong fundamentals (annual revenue growth of +8.3%, latest quarterly revenue of $5.0B, and net income of $737.0M), the company remains financially sound, limiting interpretive scope to transaction mechanics rather than company health concerns.

Group President, Europe & Developing Markets sold 20.0K shares of CL at $93.30 on 2024-11-04 for $1.9M, reducing holdings -28.9%

Tsourapas Panagiotis, Group President of Europe & Developing Markets, executed a material sale of 20,032 shares on 2024-11-04 at $93.30, reducing his stake from 69.2K to 49.2K shares—a -28.9% reduction in his post-transaction holdings. The sale occurred when CL was trading near its recent range but down 13.3% from the 52-week high and -4.8% over the prior 30 days, suggesting a liquidation during a period of price weakness. His same-ticker history at CL shows mixed timing outcomes: only 1 of 4 prior measurable sales (25%) were well-timed at the 90-day mark, with his most recent CL sale on 2024-08-08 delivering +4.8% return in 30 days but an unclear 90-day outcome. While the sale's absolute dollar magnitude ($1.9M) is material and the insider retained 49.2K shares post-transaction, the pattern of frequent sequential sells at this ticker without strong predictive timing accuracy does not establish a compelling signal of forward-looking concern about the company's fundamentals.